$NTRP Breaking News - Neurotrope Selects Worldwide Clinical Trials to Commence Services for Phase 2B Trial of Bryostatin for the Treatment of Alzheimer's Disease

NEWARK, N.J., - (http://www.financialnewsmedia.com News Alert) - Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its wholly-owned operating subsidiary, (the \"Company\") has selected Worldwide Clinical Trials (WCT) to commence the pre-patient enrollment activities for the conduct of a Phase 2b trial of the Company\'s compound bryostatin-1 for the treatment of Alzheimer\'s disease. WCT is a leading global clinical research organization with substantial experience in conducting trials in Alzheimer\'s disease.



The Company and WCT signed a letter of intent on March 30, 2015 outlining the scope of the services that WCT will provide. The Company will pay WCT approximately $300,000 for the services and related third-party costs.



Neurotrope Bioscience plans to submit its protocol to the FDA for this clinical trial in approximately 150 patients with moderately severe to severe Alzheimer\'s disease early in the second quarter of 2015. The Company expects to begin enrollment for the six month study sometime during the third quarter pending the FDA\'s review of the protocol, and plans to enter into a definitive agreement with WCT for services related to the study at the appropriate time subject to available resources.



Neurotrope Bioscience has an exclusive license to develop and commercialize bryostatin, a potent modulator of an enzyme called protein kinase C epsilon (PKCe), which has been studied extensively by the Blanchette Rockefeller Neurosciences Institute (BRNI) as a possible treatment of cognitive disorders. Based upon a number of BRNI pre-clinical and autopsy-validated human tissue studies, PKCe deficits have been implicated as a potential cause of Alzheimer\'s disease. The Company is approaching the treatment of Alzheimer\'s disease through the activation of PKCe. In animal models of Alzheimer\'s disease, activation of PKCe has been shown to improve learning and memory, induce synaptogenesis or growth of new synapses and prevent neuronal death.



Charles S. Ramat, President and Chief Executive Officer of Neurotrope, Inc. commented on the selection: \"We are extremely pleased to have entered into a letter of intent with WCT to conduct the activities required prior to enrolling patients for our planned Phase 2b Alzheimer\'s trial in moderately severe to severe...